Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Recruiting

Phase 1

Phase 2

Durvalumab & TremelimumabNeoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Sponsor:

Baylor College of Medicine

Code:

NCT05932199

Conditions

Mesothelioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Durvalumab / tremelimumab

Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Baylor College of Medicine on 2024-08-26.